Robert T. Schooley, MD
Potential Conflicts of Interest:Consultancies and Honoraria: Bristol Myers-Squibb, GlaxoSmithKline, Merck, Pfizer, Roche, Vertex, ViroLogic, Tanox, Gilead; Stock ownership or options (other than mutual funds): ViroLogic, Tanox, Vertex; Grants received: Merck, Tanox; Grants pending: Pfizer, Tibotec.
Requests for Single Reprints: Robert T. Schooley, MD, Division of Infectious Diseases, University of Colorado Health Sciences Center, 4200 East Ninth Avenue, B-168, Denver, CO 80262; e-mail, Robert.Schooley@UCHSC.edu.
Learn more about subscription options.
Register Now for a free account.
Schooley RT. Starting Highly Active Antiretroviral Therapy for HIV Infection: Is It WIHS To Wait?. Ann Intern Med. 2004;140:305–306. doi: 10.7326/0003-4819-140-4-200402170-00014
Download citation file:
Published: Ann Intern Med. 2004;140(4):305-306.
HIV, Infectious Disease.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only